Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer (opens in a new tab)

medicalxpress.com · 2026-10-26

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

17 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

17 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 13 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 8Not checkedAdding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.View evidenceHide evidence

As statedlasting survival benefit

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 8Not checkedThe findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.View evidenceHide evidence

As statedalmost eight years of follow-up

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 8Not checkedThe PEACE-1 trial included 1,173 men with de novo metastatic castration-sensitive prostate cancer, and earlier analysis showed that adding abiraterone to standard of care improved overall survival.View evidenceHide evidence

As stated1,173 men

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 8Not checkedAfter a median follow-up of 7.7 years, adding abiraterone reduced the risk of death by 25% and median overall survival was 6.1 years with abiraterone versus 4.6 years without it.View evidenceHide evidence

As stated25% risk reduction; 6.1 vs 4.6 years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 8Not checkedAmong the 710 men who received ADT plus docetaxel, adding abiraterone plus prednisone reduced the risk of death by 32%, with median survival of 6.2 years versus 4.4 years and 40.3% versus 27.1% alive at eight years.View evidenceHide evidence

As stated32% risk reduction; 6.2 vs 4.4 years; 40.3% vs 27.1% alive at eight years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 8Not checkedThe survival benefit of triplet therapy did not differ significantly by extent of disease, although the low-volume subgroup result was not statistically significant on its own.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 7 of 8Not checkedNo new long-term safety concerns were identified, though grade 3-4 hypertension and low potassium were more common with triplet therapy than with doublet therapy.View evidenceHide evidence

As stated21% vs 14% hypertension; 4% vs 1% low potassium

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 8 of 8Not checkedThe investigators suggest the results support starting treatment early rather than waiting until progression, and one author said the triplet treatment is a strong standard of care.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Abiraterone and Increased Survival in Metastatic Prostate Cancer

50 Studies Every Urologist Should Know · 2021 · Crossref

Source (opens in a new tab)

Explore all search results